Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02048150
Other study ID # 13405
Secondary ID NCI-2013-0247613
Status Completed
Phase Phase 1
First received
Last updated
Start date March 5, 2015
Est. completion date February 1, 2023

Study information

Verified date March 2023
Source City of Hope Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot clinical trial studies the best dose of anti-prostate specific membrane antigen (PSMA) monoclonal antibody MDX1201-A488 (MDX1201-A488) given before surgery to aid in visualization of the prostate. Attaching a fluorescence, a substance that emits radiation that is visible, to the anti-PMSA antibody and injecting it into the body may help identify the tumor when specialized microscopes are used.


Description:

PRIMARY OBJECTIVES: I. Determine the preferred imaging dose (if any), based on image quality and correlation with pathological findings, of intravenously administered MDX1201-A488 in a dose-escalating study (doses of 5 and 15 mg) in patients with moderate to high-risk prostate cancer prior to undergoing robotic assisted laparoscopic prostatectomy (RALP), subject to predetermined safety stopping rules. SECONDARY OBJECTIVES: I. Correlate intra-operative optical imaging (IOOI) findings with pre-operative magnetic resonance imaging (MRI) findings and clinical staging. OUTLINE: This is a dose-escalation study. Patients receive anti-PSMA monoclonal antibody MDX1201-A488 intravenously (IV) over 30 minutes on day 1 and undergo IOOI during RALP on day 5. After completion of study treatment, patients are followed up at 4-7 weeks, 3 months, 6 months, 9 months, and 1 year.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date February 1, 2023
Est. primary completion date May 10, 2018
Accepts healthy volunteers No
Gender Male
Age group 36 Years to 74 Years
Eligibility Inclusion Criteria: - Histologically confirmed adenocarcinoma of the prostate; patients with small cell, neuroendocrine, and transitional cell carcinomas are not eligible - Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than 10 years as determined by treating physician - Patients with moderate to high-risk disease as defined by D' Amico risk stratification and having at least one of the following: - Prostate-specific antigen (PSA) level > 10 ng/ml - Gleason score >= 7 - Clinical stage >= T2c - Any performance status on the Eastern Cooperative Oncology Group (ECOG) - Men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation - Bone scan without evidence of skeletal metastases - Skeletal x-ray film or MRI confirmation of absent skeletal metastases if bone scan findings are equivocal - 3Tesla (T) multiparametric MRI of the prostate performed at City of Hope (COH) within 6 week time period prior to surgery; MRI without evidence of bladder neck involvement, rectal wall involvement, or pelvic lymphadenopathy with no nodes > 1 cm - White blood cell (WBC) within normal limits - Hemoglobin (hgb) > 10 G/dL - Platelet count (PLT) > 100 K/uL - Creatinine clearance within normal limits - Serum glutamic oxaloacetic transaminase (SGOT) < 1.5 x upper limit of normal (ULN) - Serum glutamate pyruvate transaminase (SGPT) < 1.5 x ULN - Bilirubin < 1.5 x ULN - All subjects must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria: - Patients should not have any uncontrolled illness including ongoing or active infection - Prior treatment of prostate cancer including brachytherapy, radiation therapy, cryosurgery, high-intensity focused ultrasound (HIFU), or vaccine therapy - Prior pelvic surgery or radiation - Urinary incontinence requiring condom catheter use or >= 1 pad/day - Prior anti-incontinence surgery - Use of neoadjuvant hormonal manipulation - History of active co-existing non-prostatic malignancies except basal cell skin cancer or squamous cell skin cancer - Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Study Design


Intervention

Biological:
anti-PSMA monoclonal antibody MDX1201-A488
Given IV
Procedure:
robot-assisted laparoscopic surgery
Undergo RALP
Other:
diffuse optical imaging
Undergo IOOI
pharmacological study
Correlative studies
Laboratory Biomarker
Correlative studies
Questionnaire
Ancillary studies

Locations

Country Name City State
United States City of Hope Medical Center Duarte California

Sponsors (2)

Lead Sponsor Collaborator
City of Hope Medical Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Imaging ability of anti-PMSA monoclonal antibody MDX1201-A488 The main fluorescence metric will be the minimum fluorescence observed in 10 sampled high power fields from a single representative cancerous section taken per patient. Other metrics will be the mean fluorescence observed in the 10 sampled high power fields, and the median fluorescence observed. The minimum fluorescence is chosen based on the concept that the primary focus is on observing the fluorescence, and areas of peak fluorescence greatly influence the mean, and also have some influence on the median, yet may be of limited relevance. Up to 1 year
See also
  Status Clinical Trial Phase
Completed NCT02217709 - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer Phase 2
Completed NCT03077659 - Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer Phase 2
Active, not recruiting NCT03624660 - Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer N/A
Completed NCT01054079 - Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer Phase 2
Terminated NCT00512668 - Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer Phase 1
Completed NCT00087139 - Ixabepilone in Treating Patients With Metastatic Prostate Cancer Phase 2
Completed NCT00182052 - Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer Phase 3
Active, not recruiting NCT03511196 - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Early Phase 1
Active, not recruiting NCT01655836 - High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer Phase 1
Terminated NCT03535675 - Muscadine Plus (MPX) In Men With Prostate Cancer Phase 3
Terminated NCT01866423 - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 2
Completed NCT02234921 - Pilot Study of DRibble Vaccine for Prostate Cancer Patients Phase 1
Completed NCT01468532 - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT03686683 - Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Phase 3
Active, not recruiting NCT03689699 - Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) Phase 1/Phase 2
Recruiting NCT04694924 - Prospective Prostate Cancer and Patient-reported Outcomes Registry
Active, not recruiting NCT04909294 - Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma N/A
Completed NCT02225925 - Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound N/A
Completed NCT01949519 - Docetaxel and Lycopene in Metastatic Prostate Cancer Phase 1
Completed NCT01433913 - Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Phase 2